Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children
Allergy · 2024-04 · 79 (4) · 1018-1027
DOI: 10.1111/all.15985 ↗At a glance
Journal article in Allergy, published online on 2023-12-26. Written by Eckard Hamelmann and 5 co-authors. Institution: Children's Center Bethel, Bielefeld University, Bielefeld, Germany. Major MEDLINE topics: Asthma, Rhinitis, Allergic, Rhinitis, Allergic, Seasonal, Sublingual Immunotherapy. Cited 22 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: ALK, Bøge Allé 1, 2970 Hørsholm.
Topics: Kinderkrankenpflege
Abstract (original language)
Background
Allergic rhinitis (AR) is a chronic inflammatory disease of the upper airway, which progresses into allergic asthma (AA) in up to 45% of children. This analysis aimed to investigate clinical and economic benefits of sublingual allergen immunotherapy (SLIT tablets) initiated early in childhood for the treatment of AR by quantifying the long‐term reduction in new cases of AA.
Methods
A Markov model was developed to estimate the long‐term effects of SLIT tablets on the risk of developing asthma. Key parameters were primarily based on data from the GRAZAX® Asthma Prevention trial and included the age‐ and treatment‐dependent risk of developing AA as well as annual probabilities of progression/remission in AR severity. Healthcare costs were estimated using data from the REACT study.
Results
In a modelled cohort of children with moderate‐to‐severe seasonal AR initiated on SLIT tablets at ages 7 and 12, 24% and 29%, respectively, develop AA during a 20‐year period. In comparison, when initiated at age 5, 19% develop AA. Additionally, initiation of SLIT tablets at age 5 is associated with a total healthcare cost of EUR 20,429 per patient, whereas initiation at ages 7 and 12 is associated with, respectively, EUR 21,050 and EUR 22,379 per patient 20 years after AR diagnosis.
Conclusion
Initiation of SLIT tablets in early childhood is associated with a clinically meaningful and permanent reduction in new cases of AA and lower healthcare costs among children with AR. This finding supports the clinical relevance of initiating SLIT tablets early for children with AR to obtain long‐term clinical benefits.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Children's Center Bethel, Bielefeld University, Bielefeld, Germany.
- ALK, Hørsholm, Germany.
- EY Godkendt Revisionspartnerselskab, Frederiksberg, Germany.
- Center for Evidence-based Healthcare, TU Dresden, Dresden, Germany.
ORCID profiles: Eckard Hamelmann, Eva Hammerby, Anna Okkels, Jochen Schmitt
Funding
- ALK, Bøge Allé 1, 2970 Hørsholm
Cite
APA
Hamelmann, E., Hammerby, E., Scharling, K. S., Pedersen, M., Okkels, A., & Schmitt, J. (2024). Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children. Allergy, 79(4), 1018-1027. https://doi.org/10.1111/all.15985
Vancouver
Hamelmann E, Hammerby E, Scharling KS, Pedersen M, Okkels A, Schmitt J. Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children. Allergy. 2024;79(4):1018-1027. doi:10.1111/all.15985
BibTeX
@article{Hamelmann2024,
author = {Hamelmann, Eckard and Hammerby, Eva and Scharling, Katrine Skaarup and Pedersen, Mikkel and Okkels, Anna and Schmitt, Jochen},
title = {Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children},
journal = {Allergy},
year = {2024},
volume = {79},
number = {4},
pages = {1018--1027},
doi = {10.1111/all.15985}
}
EUVIMED